Downregulated RBM5 Enhances CARM1 Expression and Activates the PRKACA/GSK3β Signaling Pathway through Alternative Splicing-Coupled Nonsense-Mediated Decay.

CARM1 RBM5 alternative splicing bladder cancer nonsense-mediated mRNA decay

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
27 Dec 2023
Historique:
received: 17 11 2023
revised: 13 12 2023
accepted: 21 12 2023
medline: 11 1 2024
pubmed: 11 1 2024
entrez: 11 1 2024
Statut: epublish

Résumé

Downregulated RNA-binding motif protein 5 (RBM5) promotes the development and progression of various tumors, including bladder cancer (BC). Alternative splicing (AS) plays a crucial role in the progression of cancer by producing protein isomers with different functions or by promoting nonsense-mediated mRNA decay (NMD). However, whether RBM5 modulates the progression of BC through AS-NMD remains unexplored. In this study, we revealed that the downregulation of RBM5 expression promoted the expression of coactivator-associated arginine methyltransferase 1 (CARM1) in BC cells and tissues. Increased expression of CARM1 facilitated the activation of the Wnt/β-catenin axis and cell proliferation, which then contributed to the poor prognosis of patients with BC. Interestingly, RBM5 bound directly to CARM1 mRNA and participated in AS-NMD, downregulating the expression of CARM1. In addition, we revealed that protein kinase catalytic subunit alpha (PRKACA) functioned as a phosphorylated kinase of GSK3β, was regulated by CARM1 at the transcription level, and promoted the growth and progression of BC cells. Furthermore, in this study, we demonstrated a regulatory mechanism of Wnt/β-catenin activation through the RBM5/CARM1/PRKACA axis and identified a novel potential target for treating BC.

Identifiants

pubmed: 38201567
pii: cancers16010139
doi: 10.3390/cancers16010139
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Ya-xuan Wang
ID : H2022206402

Auteurs

Yanping Zhang (Y)

Department of Urology, The Second Hospital of Hebei Medical University, Shijiazhuang 050011, China.

Fang Li (F)

Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang 050011, China.

Zhenwei Han (Z)

Department of Urology, The Second Hospital of Hebei Medical University, Shijiazhuang 050011, China.

Zhihai Teng (Z)

Department of Urology, The Second Hospital of Hebei Medical University, Shijiazhuang 050011, China.

Chenggen Jin (C)

Department of Urology, The Second Hospital of Hebei Medical University, Shijiazhuang 050011, China.

Hao Yuan (H)

Department of Urology, The Second Hospital of Hebei Medical University, Shijiazhuang 050011, China.

Sihao Zhang (S)

Department of Urology, The Second Hospital of Hebei Medical University, Shijiazhuang 050011, China.

Kexin Sun (K)

Department of Urology, The Second Hospital of Hebei Medical University, Shijiazhuang 050011, China.

Yaxuan Wang (Y)

Department of Urology, The Second Hospital of Hebei Medical University, Shijiazhuang 050011, China.

Classifications MeSH